G-CSF vs GM-CSF: cost of adverse events makes all the difference

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.277, 2000-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

G-CSF linked to GVHD

By  

Reactions Weekly, Vol. 1, Iss. 1327, 2010-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

G-CSF not worth the extra cost in elderly patients with NHL

By  

Inpharma, Vol. 1, Iss. 1463, 2004-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

G-CSF cost-neutral for early-stage breast cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 646, 2012-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Old Friends in New Constellations - the Hematopoetic Growth Factors G-CSF, GMCSF, and EPO for the Treatment of Neurological Diseases

By  

Current Medicinal Chemistry, Vol. 15, Iss. 14, 2008-06 ,pp. : 1407-1411

Bentham Science Publishers

Access to resources Recommend Favorite

GM-CSF beneficial in idiopathic alveolar proteinosis

By  

Inpharma, Vol. 1, Iss. 1285, 2001-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite